KP Wellness
1:18 PM - Public
Edarbi (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) developed by Takeda for the treatment of hypertension to lower blood pressure in adults. Edarbi lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone, which naturally exists within the body. When Edarbi blocks the angiotensin II receptor, blood vessels can stay relaxed and open, and blood pressure can be reduced. Edarbi is indicated for the treatment of hypertension to lower blood pressure in adults, either alone or in combination with other antihypertensive agents. The recommended dose of Edarbi in adults is 80 mg taken once daily. A starting dose of 40 mg may be appropriate for patients on high doses of diuretics. Edarbi recently received Marketing Authorization in Europe and is currently available in the United States and Mexico.
Edarbyclor (azilsartan medoxomil and chlorthalidone) is a fixed-dose combination therapy for the treatment of hypertension that combines azilsartan medoxomil and chlorthalidone in a single tablet. Chlorthalidone reduces the amount of water in the body by increasing the flow of urine, which helps lower blood pressure. Edarbyclor is indicated for the treatment of hypertension to lower blood pressure and may be used as an initial therapy if a patient is likely to need multiple drugs to achieve blood pressure control. The recommended starting dose of Edarbyclor in adults is 40/12.5 mg taken orally once daily. The maximum recommended dose is 40/25 mg.
http://www.drugs.com/newdrugs/fda-approves-edarbyclor-azilsartan-medoxomil-chlorthalidone-hypertension-3005.html
Edarbyclor (azilsartan medoxomil and chlorthalidone) is a fixed-dose combination therapy for the treatment of hypertension that combines azilsartan medoxomil and chlorthalidone in a single tablet. Chlorthalidone reduces the amount of water in the body by increasing the flow of urine, which helps lower blood pressure. Edarbyclor is indicated for the treatment of hypertension to lower blood pressure and may be used as an initial therapy if a patient is likely to need multiple drugs to achieve blood pressure control. The recommended starting dose of Edarbyclor in adults is 40/12.5 mg taken orally once daily. The maximum recommended dose is 40/25 mg.
http://www.drugs.com/newdrugs/fda-approves-edarbyclor-azilsartan-medoxomil-chlorthalidone-hypertension-3005.html
KP Wellness
1:15 PM - Public
The FDA has approved azilsartan medoxomil (Edarbi, Takeda) for the treatment of high blood pressure. The new angiotensin II receptor blocker (ARB) will be available in 80 milligram and 40 mg doses. The recommended dose is 80 mg once daily. The 40 mg dose is used in combination with a diuretic.
http://cardiobrief.org/2011/02/25/fda-approves-azilsartan-medoxomil-edarbi-for-high-blood-pressure/
http://cardiobrief.org/2011/02/25/fda-approves-azilsartan-medoxomil-edarbi-for-high-blood-pressure/
KP Wellness
1:13 PM - Public
Azilsartan (INN, codenamed TAK-536) is an angiotensin II receptor antagonist used in the treatment of hypertension that was developed by Takeda.
http://en.wikipedia.org/wiki/Azilsartan
http://en.wikipedia.org/wiki/Azilsartan
KP Wellness
1:12 PM - Public
Edarbi (azilsartan medoxomil), a prodrug, is hydrolyzed to azilsartan in the gastrointestinal tract during absorption. Azilsartan is a selective AT1 subtype angiotensin II receptor antagonist.
http://www.rxlist.com/edarbi-drug.htm
http://www.rxlist.com/edarbi-drug.htm
KP Wellness
1:08 PM - Public
Edarbyclor (azilsartan medoxomil and chlorthalidone)
It is the only fixed-dose therapy in the United States to combine an angiotensin II receptor blocker with chlorthalidone in a once-daily, single tablet.
http://ajw.asahi.com/article/economy/biz_briefs/AJ201202070041
It is the only fixed-dose therapy in the United States to combine an angiotensin II receptor blocker with chlorthalidone in a once-daily, single tablet.
http://ajw.asahi.com/article/economy/biz_briefs/AJ201202070041
KP Wellness
1:06 PM - Public
Edarbyclor differs from other treatments by combining a receptor blocker and a diuretic in one pill
http://www.chicagotribune.com/news/local/suburbs/deerfield/chi-jnt389495-deerfield-fixed-dose-20120626,0,1324032.story
http://www.chicagotribune.com/news/local/suburbs/deerfield/chi-jnt389495-deerfield-fixed-dose-20120626,0,1324032.story
KP Wellness
1:01 PM - Public
Edarbyclor phase 3 study published online in the American Heart Association journal Hypertension
http://www.marketwatch.com/story/edarbyclor-azilsartan-medoxomil-and-chlorthalidone-head-to-head-data-published-in-hypertension-2012-06-19
http://www.marketwatch.com/story/edarbyclor-azilsartan-medoxomil-and-chlorthalidone-head-to-head-data-published-in-hypertension-2012-06-19
KP Wellness
12:52 PM - Public
Primary hypertension
Secondary hypertension
Hypertensive crises
In pregnancy
In infants and children
In the elderly
http://en.wikipedia.org/wiki/Hypertension
Secondary hypertension
Hypertensive crises
In pregnancy
In infants and children
In the elderly
http://en.wikipedia.org/wiki/Hypertension
KP Wellness
12:39 PM - Public
Contents
1 Diuretics
2 Adrenergic receptor antagonists
3 Calcium channel blockers
4 Renin Inhibitors
5 ACE inhibitors
6 Angiotensin II receptor antagonists
7 Aldosterone antagonists
8 Vasodilators
9 Alpha-2 agonists
http://en.wikipedia.org/wiki/Antihypertensive_drug
1 Diuretics
2 Adrenergic receptor antagonists
3 Calcium channel blockers
4 Renin Inhibitors
5 ACE inhibitors
6 Angiotensin II receptor antagonists
7 Aldosterone antagonists
8 Vasodilators
9 Alpha-2 agonists
http://en.wikipedia.org/wiki/Antihypertensive_drug
KP Wellness
12:30 PM - Public
Abstract
A 71-year-old hypertensive patient experienced a severe hypertensive crisis. His blood pressure was 300/200 mm Hg three days after nifedipine therapy was discontinued. He had been taking nifedipine together with methyldopa. During five months on the combined treatment, his blood pressure had not risen higher than 170/100 mm Hg. A severe hypertensive crisis following abrupt nifedipine withdrawal has not been previously reported, to our knowledge. We recommend that caution be used when abrupt cessation of nifedipine therapy is considered in the treatment of hypertension.
http://www.ncbi.nlm.nih.gov/pubmed/3947200
A 71-year-old hypertensive patient experienced a severe hypertensive crisis. His blood pressure was 300/200 mm Hg three days after nifedipine therapy was discontinued. He had been taking nifedipine together with methyldopa. During five months on the combined treatment, his blood pressure had not risen higher than 170/100 mm Hg. A severe hypertensive crisis following abrupt nifedipine withdrawal has not been previously reported, to our knowledge. We recommend that caution be used when abrupt cessation of nifedipine therapy is considered in the treatment of hypertension.
http://www.ncbi.nlm.nih.gov/pubmed/3947200
KP Wellness
12:28 PM - Public
Hypertensive Crises
Challenges and Management
http://chestjournal.chestpubs.org/content/131/6/1949.full
The Diagnosis and Management of Hypertensive Crises
http://chestjournal.chestpubs.org/content/118/1/214.full
Severe hypertension without acute end-organ damage is referred to as a hypertensive urgency and is usually treated with oral antihypertensive agents.
The preferred agents in the Treatment of Hypertensive Emergencies include labetalol, esmolol, nicardipine, and fenoldopam.
Agents such as nifedipine and hydralazine should be abandoned because these agents are associated with significant toxicities and/or side effect profile.
Challenges and Management
http://chestjournal.chestpubs.org/content/131/6/1949.full
The Diagnosis and Management of Hypertensive Crises
http://chestjournal.chestpubs.org/content/118/1/214.full
Severe hypertension without acute end-organ damage is referred to as a hypertensive urgency and is usually treated with oral antihypertensive agents.
The preferred agents in the Treatment of Hypertensive Emergencies include labetalol, esmolol, nicardipine, and fenoldopam.
Agents such as nifedipine and hydralazine should be abandoned because these agents are associated with significant toxicities and/or side effect profile.
No comments:
Post a Comment